Keywords
How to Cite
Abstract
Liver cirrhosis is the terminal stage of chronic liver disease, and its prognosis is largely determined by the development of decompensation phenotypes. Complications such as ascites, variceal bleeding, spontaneous bacterial peritonitis, and hepatic encephalopathy markedly worsen patient survival. In recent years, systemic inflammation, disruption of the gut-liver immune axis, and cytokine imbalance have been recognized as major contributors to the clinical course of cirrhosis. In particular, the Th17/IL-23/IL-17 signaling pathway and the IL-6 cascade are increasingly regarded as factors associated with fibrosis progression, infectious complications, and adverse outcomes. This thesis highlights the prognostic significance of immunogenetic markers, including IL-23R, IL-17A, IL-17F, and IL-6, for early assessment of decompensation risk in liver cirrhosis. The integration of molecular-genetic indicators with conventional clinical criteria represents a promising strategy for personalized prognosis and risk stratification.
References
1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. doi:10.1016/j.jhep.2018.03.024.
2. Sun HQ, Zhang JY, Zhang H, Zou ZS, Wang FS, Jia JH. Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis. J Viral Hepat. 2012;19(6):396–403. doi:10.1111/j.1365-2893.2011.01561.x.
3. Xiao S, Zhou L, Li J, et al. Gene polymorphisms of inflammatory factors in liver cirrhosis. Front Genet. 2023;14:1140427. doi:10.3389/fgene.2023.1140427.
4. Xia C, Lou G, Ye B, Chen F, Chen Z, Liu Y, et al. Genetic polymorphisms of interleukin-6 influence the development of hepatitis B virus-related liver cirrhosis in the Han Chinese population. Infect Genet Evol. 2020;84:104331. doi:10.1016/j.meegid.2020.104331.
5. Kornfehl A, et al. Decreasing interleukin-6 levels after TIPS predict outcomes in patients with cirrhosis. JHEP Reports. 2025.
6. Sharma C, et al. Assessment of interleukin-6 levels in patients with liver cirrhosis. 2025.
7. Serum pro-inflammatory cytokine interleukin-6 level is a predictor of further decompensation and mortality in patients with liver cirrhosis. 2025.